A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy

PHASE3CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

May 17, 2021

Primary Completion Date

September 14, 2023

Study Completion Date

July 23, 2024

Conditions
Diabetic Peripheral Neuropathy
Interventions
BIOLOGICAL

Engensis

Injections with Engensis in study VMDN-003-2

OTHER

Placebo

Injections with Placebo in study VMDN-003-2

Trial Locations (16)

10314

Richmond Behavioral Associates, Staten Island

20110

Manassas Clinical Research Center, Manassas

23219

Dominion Medical Associates, Richmond

23510

Eastern Virginia Medical School, Norfolk

33756

Innovative Research of West Florida, Inc., Clearwater

57702

Health Concepts, Rapid City

62269

Gateway Clinical Trials, LLC, O'Fallon

62704

Foot & Ankle Center of Illinois, Springfield

63005

Clinical Research Professionals, Chesterfield

72205

Clinical Trials - Little Rock, Little Rock

75165

ClinPoint Trials LLC, Waxahachie

77030

Nerve and Muscle Center of Texas, Houston

78501

Futuro Clinical Trials, McAllen

85053

Arizona Research Center, Phoenix

90048

California Medical Clinic for Headache, Los Angeles

95821

Clinical Trials Research - Sacramento, Sacramento

All Listed Sponsors
lead

Helixmith Co., Ltd.

INDUSTRY